Blacksmith Medicines is a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes. The Blacksmith metalloenzyme platform is a unique drug discovery engine purpose-built to target the largest and most diverse group of enzymes in the human genome.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/21 | undisclosed | Seed |
Alexandria Venture Investments Eli Lilly and Company Evotec MagnaSci Ventures MP Healthcare Venture Management | undisclosed |
